Aquestive's Anaphylm Hit by FDA CRL, Delaying Approval and Validating Bear-Case Risks

What happened

Aquestive Therapeutics disclosed in its Q4 earnings call that the FDA issued a Complete Response Letter for Anaphylm, forcing management to outline a resubmission plan for Q3 2026. This regulatory setback directly triggers the bear scenario highlighted in the DeepValue report, which rated the stock a potential sell due to high approval and funding risks. The delay pushes back Anaphylm's revenue timeline, exacerbating the company's financial strain from persistent losses, a stockholders' deficit, and rising SG&A costs. Competitive pressures from neffy and generic auto-injectors will intensify during this period, threatening future market share. Consequently, the path to profitability is now more uncertain and dependent on successful regulatory navigation and additional capital raises.

Implication

Investors should reassess valuations downward as the approval delay shifts probability towards the bear case, with equity potentially trending toward $3.50. Additional equity raises or debt refinancing are likely to sustain operations, increasing dilution and subordinating shareholder returns. Competitive dynamics may worsen as neffy consolidates market share during the delay, squeezing Anaphylm's future pricing and access. Management's execution on resubmission is critical, but their track record of aggressive, dilutive funding offers little margin for error. Overall, the investment thesis weakens, suggesting a defensive stance until clearer regulatory and commercial milestones emerge.

Thesis delta

The FDA's CRL transforms the thesis from a binary approval bet into a story of prolonged regulatory uncertainty and heightened financial stress. This increases the likelihood of the bear scenario, capping upside near base-case valuations and raising downside risk toward distressed levels.